| Monograph Title
| Section Head
| Scientific Liaison
|
| ALPRAZOLAM PF 33(5) Pg. 868 |
USP Reference standards <11> |
|
| ALPRAZOLAM PF 33(5) Pg. 868 |
Identification |
|
| ALPRAZOLAM PF 33(5) Pg. 868 |
Loss on drying <731> |
|
| ALPRAZOLAM PF 33(5) Pg. 868 |
Chromatographic purity |
|
| ALPRAZOLAM PF 33(5) Pg. 868 |
Related compounds |
|
| ALPRAZOLAM PF 33(5) Pg. 868 |
Assay |
|
| ALUMINA, MAGNESIA, AND SIMETHICONE ORAL
SUSPENSION PF 33(5) Pg. 871 |
Defoaming activity |
|
| ALUMINA, MAGNESIA, AND SIMETHICONE
TABLETS PF 33(5) Pg. 871 |
Defoaming activity |
|
| ALUMINA, MAGNESIA, AND SIMETHICONE
TABLETS PF 33(5) Pg. 871 |
Defoaming activity |
|
| ALUMINA, MAGNESIA, CALCIUM CARBONATE,
AND SIMETHICONE TABLETS PF 33(5) Pg. 870 |
Defoaming activity |
|
| ALUMINA, MAGNESIA, CALCIUM CARBONATE,
AND SIMETHICONE TABLETS PF 33(5) Pg. 870 |
Defoaming activity |
|
| AMILORIDE HYDROCHLORIDE AND
HYDROCHLOROTHIAZIDE TABLETS PF 33(4) Pg. 636 |
Dissolution <711> |
|
| ATOVAQUONE PF 33(4) Pg. 637 |
Heavy metals |
|
| AVOBENZONE PF 33(5) Pg. 872 |
Assay |
|
| AZTREONAM PF 33(5) Pg. 872 |
Definition |
|
| AZTREONAM PF 33(5) Pg. 872 |
Labeling |
|
| AZTREONAM PF 33(5) Pg. 872 |
Identification, Infrared Absorption <197K> |
|
| AZTREONAM PF 33(5) Pg. 872 |
Water, Method I <921> |
|
| BACITRACIN PF 33(5) Pg. 873 |
Chemical Info |
|
| BACITRACIN PF 33(5) Pg. 873 |
Definition |
|
| BACITRACIN PF 33(5) Pg. 873 |
Identification |
|
| BACITRACIN PF 33(5) Pg. 873 |
Residue on ignition <281> |
|
| BACITRACIN PF 33(5) Pg. 873 |
Composition |
|
| BACITRACIN PF 33(5) Pg. 873 |
Definition |
|
| BACITRACIN ZINC PF 33(5) Pg. 875 |
Definition |
|
| BACITRACIN ZINC PF 33(5) Pg. 875 |
Identification |
|
| BACITRACIN ZINC PF 33(5) Pg. 875 |
Composition |
|
| BACITRACIN ZINC PF 33(5) Pg. 875 |
Definition |
|
| BICALUTAMIDE PF 33(5) Pg. 876 |
Title |
|
| BICALUTAMIDE PF 33(5) Pg. 876 |
Chemical Info |
|
| BICALUTAMIDE PF 33(5) Pg. 876 |
Definition |
|
| BICALUTAMIDE PF 33(5) Pg. 876 |
Packaging and storage |
|
| BICALUTAMIDE PF 33(5) Pg. 876 |
USP Reference standards <11> |
|
| BICALUTAMIDE PF 33(5) Pg. 876 |
Identification |
|
| BICALUTAMIDE PF 33(5) Pg. 876 |
Water, Method I <921> |
|
| BICALUTAMIDE PF 33(5) Pg. 876 |
Residue on ignition <281> |
|
| BICALUTAMIDE PF 33(5) Pg. 876 |
Heavy metals, Method II <231> |
|
| BICALUTAMIDE PF 33(5) Pg. 876 |
Related compounds |
|
| BICALUTAMIDE PF 33(5) Pg. 876 |
Assay |
|
| BISMUTH SUBSALICYLATE MAGMA PF 33(4) Pg.
638 |
Packaging and storage |
|
| BOVINE ACELLULAR DERMAL MATRIX PF 33(5)
Pg. 898 |
Title |
|
| BOVINE ACELLULAR DERMAL MATRIX PF 33(5)
Pg. 898 |
Definition |
|
| BOVINE ACELLULAR DERMAL MATRIX PF 33(5)
Pg. 898 |
Packaging and storage |
|
| BOVINE ACELLULAR DERMAL MATRIX PF 33(5)
Pg. 898 |
Labeling |
|
| BOVINE ACELLULAR DERMAL MATRIX PF 33(5)
Pg. 898 |
USP Reference standards <11> |
|
| BOVINE ACELLULAR DERMAL MATRIX PF 33(5)
Pg. 898 |
USP Authentic Visual References <11> |
|
| BOVINE ACELLULAR DERMAL MATRIX PF 33(5)
Pg. 898 |
Bacterial endotoxins <85> |
|
| BOVINE ACELLULAR DERMAL MATRIX PF 33(5)
Pg. 898 |
Sterility <71> |
|
| BOVINE ACELLULAR DERMAL MATRIX PF 33(5)
Pg. 898 |
Histological evaluation |
|
| BOVINE ACELLULAR DERMAL MATRIX PF 33(5)
Pg. 898 |
Protein determination |
|
| BOVINE ACELLULAR DERMAL MATRIX PF 33(5)
Pg. 898 |
Lipid analysis |
|
| BOVINE ACELLULAR DERMAL MATRIX PF 33(5)
Pg. 898 |
Moisture content |
|
| BOVINE ACELLULAR DERMAL MATRIX PF 33(5)
Pg. 898 |
Ash determination |
|
| BOVINE ACELLULAR DERMAL MATRIX PF 33(5)
Pg. 898 |
Carbohydrates |
|
| BOVINE ACELLULAR DERMAL MATRIX PF 33(5)
Pg. 898 |
Gel electrophoresis |
|
| BOVINE ACELLULAR DERMAL MATRIX PF 33(5)
Pg. 898 |
Tensile strength |
|
| BOVINE ACELLULAR DERMAL MATRIX PF 33(5)
Pg. 898 |
Suture retention force |
|
| BOVINE ACELLULAR DERMAL MATRIX PF 33(5)
Pg. 898 |
Thermal analysis |
|
| BOVINE ACELLULAR DERMAL MATRIX PF 33(5)
Pg. 898 |
Visual inspection |
|
| BOVINE ACELLULAR DERMAL MATRIX PF 33(5)
Pg. 898 |
Hydration rate |
|
| BUPROPION HYDROCHLORIDE PF 33(4) Pg. 638 |
Related compounds |
|
| CALCIUM SILICATE PF 33(3) Pg. 484 |
Limit of fluoride |
|
| CALCITONIN SALMON PF 33(5) Pg. 878 |
Packaging and storage |
|
| CALCITONIN SALMON PF 33(5) Pg. 878 |
Labeling |
|
| CALCITONIN SALMON PF 33(5) Pg. 878 |
Amino acid profile |
|
| CALCITONIN SALMON PF 33(5) Pg. 878 |
Peptide mapping |
|
| CALCITONIN SALMON PF 33(5) Pg. 878 |
Acetic acid content <503> |
|
| CALCITONIN SALMON PF 33(5) Pg. 878 |
Related peptides and other related substances |
|
| CALCIUM CARBONATE, MAGNESIA, AND
SIMETHICONE TABLETS PF 33(5) Pg. 888 |
Defoaming activity |
|
| CALCIUM CARBONATE, MAGNESIA, AND
SIMETHICONE TABLETS PF 33(5) Pg. 888 |
Defoaming activity |
|
| CEFACLOR CHEWABLE TABLETS PF 32(2) Pg.
314 |
Definition |
|
| CEFACLOR CHEWABLE TABLETS PF 32(2) Pg.
314 |
Packaging and storage |
|
| CEFACLOR CHEWABLE TABLETS PF 32(2) Pg.
314 |
Labeling |
|
| CEFACLOR CHEWABLE TABLETS PF 32(2) Pg.
314 |
USP Reference standards |
|
| CEFACLOR CHEWABLE TABLETS PF 32(2) Pg.
314 |
Identification |
|
| CEFACLOR CHEWABLE TABLETS PF 32(2) Pg.
314 |
Uniformity of dosage units |
|
| CEFACLOR CHEWABLE TABLETS PF 32(2) Pg.
314 |
Water |
|
| CEFACLOR CHEWABLE TABLETS PF 32(2) Pg.
314 |
Related compounds |
|
| CEFACLOR CHEWABLE TABLETS PF 32(2) Pg.
314 |
Assay |
|
| CEFACLOR CHEWABLE TABLETS PF 33(4) Pg.
641 |
Title |
|
| CEFACLOR CHEWABLE TABLETS PF 33(4) Pg.
641 |
Definition |
|
| CEFACLOR CHEWABLE TABLETS PF 33(4) Pg.
641 |
Labeling |
|
| CEFACLOR CHEWABLE TABLETS PF 33(4) Pg.
641 |
Related compounds |
|
| CEFACLOR CHEWABLE TABLETS PF 33(4) Pg.
641 |
Assay |
|
| CHAMOMILE PF 33(4) Pg. 688 |
Definition |
|
| CHAMOMILE PF 33(4) Pg. 688 |
Identification |
|
| CHAMOMILE PF 33(4) Pg. 688 |
Microbial enumeration <2021> |
|
| CHAMOMILE PF 33(4) Pg. 688 |
Absence of specified microorganisms <2022> |
|
| CHAMOMILE PF 33(4) Pg. 688 |
Volatile oil content <561> |
|
| CHAMOMILE PF 33(4) Pg. 688 |
Content of apigenin-7-glucoside |
|
| CHAMOMILE PF 33(4) Pg. 688 |
Content of bisabolane derivatives |
|
| CICLOPIROX OLAMINE PF 33(4) Pg. 643 |
Related compounds |
|
| CICLOPIROX PF 33(4) Pg. 642 |
Related compounds |
|
| CLOZAPINE PF 33(5) Pg. 893 |
USP Reference standards <11> |
|
| CLOZAPINE PF 33(5) Pg. 893 |
Identification |
|
| CLOZAPINE PF 33(5) Pg. 893 |
Chromatographic purity |
|
| CLOZAPINE PF 33(5) Pg. 893 |
Related compounds |
|
| COLESTIPOL HYDROCHLORIDE FOR ORAL
SUSPENSION PF 33(5) Pg. 896 |
Identification, Infrared Absorption <197K> |
|
| COLESTIPOL HYDROCHLORIDE FOR ORAL
SUSPENSION PF 33(5) Pg. 896 |
Other requirements |
|
| COLESTIPOL HYDROCHLORIDE FOR ORAL
SUSPENSION PF 33(5) Pg. 896 |
Water-soluble substances |
|
| COLESTIPOL HYDROCHLORIDE PF 33(5) Pg.
895 |
Identification |
|
| COLESTIPOL HYDROCHLORIDE PF 33(5) Pg.
895 |
Water-soluble substances |
|
| COLESTIPOL HYDROCHLORIDE TABLETS PF
33(5) Pg. 896 |
Title |
|
| COLESTIPOL HYDROCHLORIDE TABLETS PF
33(5) Pg. 896 |
Definition |
|
| COLESTIPOL HYDROCHLORIDE TABLETS PF
33(5) Pg. 896 |
Packaging and storage |
|
| COLESTIPOL HYDROCHLORIDE TABLETS PF
33(5) Pg. 896 |
USP Reference standards <11> |
|
| COLESTIPOL HYDROCHLORIDE TABLETS PF
33(5) Pg. 896 |
Identification, Infrared Absorption <197K> |
|
| COLESTIPOL HYDROCHLORIDE TABLETS PF
33(5) Pg. 896 |
Uniformity of dosage units |
|
| COLESTIPOL HYDROCHLORIDE TABLETS PF
33(5) Pg. 896 |
pH <791> |
|
| COLESTIPOL HYDROCHLORIDE TABLETS PF
33(5) Pg. 896 |
Cholate binding capacity |
|
| CUPRIC SULFATE PF 33(5) Pg. 898 |
Limit of calcium |
|
| CYROMAZINE PF 33(4) Pg. 644 |
Title |
|
| CYROMAZINE PF 33(4) Pg. 644 |
Chemical Info |
|
| CYROMAZINE PF 33(4) Pg. 644 |
Definition |
|
| CYROMAZINE PF 33(4) Pg. 644 |
Packaging and storage |
|
| CYROMAZINE PF 33(4) Pg. 644 |
Labeling |
|
| CYROMAZINE PF 33(4) Pg. 644 |
USP Reference standards <11> |
|
| CYROMAZINE PF 33(4) Pg. 644 |
Identification |
|
| CYROMAZINE PF 33(4) Pg. 644 |
Melting range <741> |
|
| CYROMAZINE PF 33(4) Pg. 644 |
Loss on drying <731> |
|
| CYROMAZINE PF 33(4) Pg. 644 |
Residue on ignition <281> |
|
| CYROMAZINE PF 33(4) Pg. 644 |
Assay |
|
